Multiple Sclerosis: India and China’s Prevalent
Cases to Witness Highest Growth by 2023, says Publisher. The number of multiple
sclerosis (MS) prevalent cases across the ten major markets (10MM) will
increase from 904,908 in 2013 to 940,413 by 2023, at an Annual Growth Rate
(AGR) of 0.39%, says research and consulting firm Publisher.
The company’s latest report* states that
among the 10MM (the US, Canada, France, Germany, Italy, Spain, the UK, Japan,
China and India), India will have the highest increase in prevalent cases, with
an AGR of almost 2%, followed by Spain and China, with AGRs of 1.05% and 0.93%,
respectively.
Despite having lower AGRs, Publisher
epidemiologists forecast that the US will have the highest number of prevalent
cases of MS by 2023, with 303,343, followed by Canada with 142,199 and Germany
with 140,209.
According to Senior Epidemiologist,
says: “Regional differences in MS prevalence and incidence could be due to
several factors, including the differing diagnostic criteria used, the
availability of medical technology, genetic and environmental risk factors, the
frequency of comorbidities, and population age and sex structures.”
Although China and India had
significantly lower MS incidence rates than the other countries in 2013, their
large population sizes are the main factor contributing to their high number of
incident cases, according to Publisher.
According to Senior Epidemiologist
continues: “With less availability of diagnostic MRI technology in China and
India, compared with western countries, case ascertainment in these countries
is not as precise. Less accurate case diagnosis can result in diseases, such as
neuromyelitis optica, being misclassified as MS, and may have resulted in an
overestimation of the latter’s incidence in China and India.”
Low MS prevalence proportions in these
countries could also be related to the genetic makeup of these populations, as
MS is more commonly diagnosed in Caucasians than individuals of any other
race/ethnicity. This is even the case in western countries where MRI technology
is widely available.
EpiCast Report: Multiple Sclerosis -
Epidemiology Forecast to 2023 report provides an overview of the risk factors
and comorbidities of Multiple Sclerosis, and global and historical trends in
the 10 major markets (the US, France, Germany, Italy, Spain, the UK, Japan,
Canada, China and India). It includes a 10-year epidemiological forecast of MS
prevalent and incident cases segmented by sex and age.
This report was built using data and
information sourced from proprietary databases, primary and secondary research,
and in-house analysis conducted by Publisher’s team of industry experts.
Find
All Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.